Biotech News
Related news
XENEXenon2026-09-03 20:01 EST
Xenon to Present at Wells Fargo Healthcare Conference
XENEXenon2026-09-17 20:01 EST
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
CGTXCognition Therapeutics2026-09-08 11:30 EST
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
HRMYHarmony Biosciences2026-09-03 12:05 EST
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
VYGRVoyager Therapeutics2026-09-01 12:00 EST
Voyager to Present at Upcoming Investor Conferences
ANNXAnnexon, Inc.2026-07-14 20:05 EST
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
AXSMAxsome2026-08-31 11:00 EST
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
CGTXCognition Therapeutics2026-07-13 11:30 EST
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Xenon
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....
Recent company news
XENEXenon2026-09-21 20:01 EST
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
XENEXenon2026-09-17 20:01 EST
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
XENEXenon2026-09-03 20:01 EST
Xenon to Present at Wells Fargo Healthcare Conference
XENEXenon2026-08-28 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XENEXenon2026-08-26 20:01 EST
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
Stock data
- Close
- 39.75 USD
- Market cap
- 5.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States